GoldenGolden
Pionyr Immunotherapeutics

Pionyr Immunotherapeutics

Pionyr Immunotherapeutics is a San Francisco-based biotechnology company and developer of cancer immunotherapies designed to target the tumor microenvironment.

Pionyr Immunotherapeutics is a clinical stage company that is developing cancer immunotherapies that target the tumor microenvironment to improve the antitumor immunity of the human body. Its approach, Myeloid Tuning™, has been designed to improve the immune system’s anti-tumor response by altering the myeloid infiltrate of the tumor microenvironment with high specificity and for specific purposes.

Pionyr has a deep and diversified pipeline of myeloid targeting monoclonal antibody therapeutics. The PY314 and PY159 programs, targeting TREM2 and TREM1 respectively, have been cleared by the FDA to initiate clinical trials.

The Myeloid TuningTM technology of Pionyr builds on the discovery that altering the tumor microenvironment to favor immune-activating cells over immune-suppressing cells improves the ability of the body to combat cancer.

Timeline

December 2017
Pionyr Immunotherapeutics raises a $62,000,000 series B round from Mission Bay Capital, New Enterprise Associates, OrbiMed, Osage University Partners, SV Health Investors, Sofinnova Ventures and Vida Ventures.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Melanie Senior
April 1, 2021
Nature Biotechnology
Private biotech firms are awash with funding, raising record-breaking sums in 2020. Melanie Senior reports.
BioSpace
November 18, 2020
BioSpace
Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body's antitumor immunity by altering the composition and function
Ben Adams
June 23, 2020
FierceBiotech
As it continues with its small to medium-sized biotech deals, Gilead has put down $275 million for a 49.9% share in immuno-oncology biotech Pionyr with the option to buy it out completely should it pass muster in early clinical tests.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.